Organon & Co. (OGN)

Market Cap	4.71B
Revenue (ttm)	6.26B
Net Income (ttm)	1.02B
Shares Out	255.64M
EPS (ttm)	3.99
PE Ratio	4.62
Forward PE	4.26
Dividend	$1.12 (6.08%)
Ex-Dividend Date	Feb 23, 2024

Volume	1,449,559
Open	18.62
Previous Close	18.71
Day's Range	18.20 - 18.73
52-Week Range	10.84 - 24.79
Beta	0.79
Analysts	Buy
Price Target	22.50 (+22.15%)
Earnings Date	May 2, 2024

About OGN

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple o...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 10,000
• Stock Exchange: NYSE
• Ticker Symbol: OGN

Financial Performance

In 2023, Organon & Co.'s revenue was $6.26 billion, an increase of 1.44% compared to the previous year's $6.17 billion. Earnings were $1.02 billion, an increase of 11.56%.

Analyst Forecast

According to 4 analysts, the average rating for OGN stock is "Buy." The 12-month stock price forecast is $22.5, which is an increase of 22.15% from the latest price.

Price Target

$22.5

(22.15% upside)

Analyst Consensus: Buy